‘Huddle Up for Alzheimer’s’ Campaign Encourages Clinical Trial Participation

‘Huddle Up for Alzheimer’s’ Campaign Encourages Clinical Trial Participation
A National Football League broadcaster and former NFL player is urging Americans to “Huddle Up for New Alzheimer’s Treatments” by participating in clinical trials testing new drugs that may potentially treat the degenerative brain disease. The new educational and awareness-raising campaign teams Solomon Wilcots with Axovant Sciences, Ltd., and patient advocacy groups in support of late-stage research such as the Mindset study. The Phase 3 study, led by Axovant, is evaluating the oral drug RVT-101 in combination with donepezil, a standard therapy, in mild-to-moderate Alzheimer’s disease patients. A control group of patients will receive donepezil treatment alone. This six-month, double-blind Mindset study will be followed by a 12-month open-label extension study, and trial results may be make the drug eligible for approval by the U.S. Food and Drug Administration. The clinical trial (NCT02585934) is currently recruiting and hopes to enroll up to 1,150 Alzheimer's patients. Its anticipated completion date is October 2017. RVT-101 has already been included in 13 previous clinical trials and administered to more than 1,250 patients, who tolerated the drug well, the company reports. “Bringing new Alzheimer's treatments to market requires the help of patients and caregivers who participate in late-stage clinical research studies,” said the study's lead researcher, Ilise Lombardo, MD, in a press release.  “Education and teamwork
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *